ALECTOR INC

Company Overview

Alector Inc. (ALEC) is a clinical-stage biotechnology company focused on neurodegenerative and immune-related programs (notably latozinemab/INFRONT‑3 and AL101/PROGRESS‑AD) and remains pre‑revenue from product sales. Recent results show declining collaboration revenue and materially lower R&D spend following program wind‑downs (e.g., AL002) and a March 2025 workforce reduction; cash and marketable securities were $307.3M at June 30, 2025 with $10M drawn on a $50M loan facility. Near‑term material events include INFRONT‑3 topline expected mid‑Q4 2025 and PROGRESS‑AD completion in 2026, and management notes cash runway into H2 2027 but substantial uncertainty that could require additional financing sooner.

Executive Compensation Practices

As a pre‑revenue, R&D‑intensive biotech in the Healthcare / Biotechnology sector, Alector’s compensation is likely equity‑heavy (stock options/RSUs) to conserve cash, with significant long‑term incentive awards tied to development milestones, regulatory filings, and collaboration achievements (e.g., GSK milestone triggers and clinical readouts such as INFRONT‑3). Short‑term pay will tend to be modest relative to later‑stage peers, while bonuses or special retention grants are commonly used after headcount reductions to retain key talent; severance and change‑in‑control provisions may also be meaningful given program transitions. The company’s compensation committee will probably emphasize clinical progress metrics (enrollment, topline efficacy/safety, co‑primary endpoint achievement) and cash stewardship (operating cash use and maintaining runway) as primary performance drivers.

Insider Trading Considerations

Insider trading patterns at Alector should be monitored around discrete, high‑impact events: clinical data releases (INFRONT‑3 mid‑Q4 2025), milestone announcements tied to collaboration revenue, and financing activity (ATM offerings, equity raises or draws under the loan facility), any of which can cause large share‑price moves. Expect insiders to rely on formal blackout periods and 10b5‑1 trading plans to manage legally defensible trades because personnel often possess material nonpublic information on trial progress and collaboration milestones; adoption of such plans is common in biotech. Also consider that collaboration agreements and confidentiality obligations (e.g., with GSK) may impose additional informal or contractual trading constraints, and that equity‑based compensation combined with runway pressure can increase the likelihood of insider sales following public financings or to cover tax liabilities on option exercises.